Related Experiment Videos
Immune responses to hybrid maltose-binding proteins
D O'Callaghan1, P Martineau, C Fayolle
1Programmation Moléculaire et Toxicologie Génétique (CNRS URA 1444), Paris, France.
Vaccine
|January 1, 1993
Summary
Genetically engineered hybrid proteins using Escherichia coli maltose-binding protein (MalE) can elicit specific immune responses. Bacterial delivery of these hybrid proteins induces both B-cell and T-cell immunity.
Area of Science:
- Biotechnology
- Immunology
- Protein Engineering
Background:
- The Escherichia coli maltose-binding protein (MalE) is a versatile carrier protein.
- MalE accepts genetic fusions and peptide insertions at permissive sites, enabling the creation of hybrid proteins.
Purpose of the Study:
- To engineer hybrid proteins by inserting viral epitopes into MalE.
- To evaluate the immunogenicity and immune responses induced by these hybrid proteins, particularly when delivered by live bacteria.
Main Methods:
- Genetically inserting immunogenic viral B- and T-cell epitopes into two permissive sites (amino acid sites 133 and 303) of the MalE protein.
- Purifying the resulting hybrid MalE proteins.
- Delivering hybrid proteins using live bacterial vectors (E. coli K12 and aroA Salmonella typhimurium).
Main Results:
- The engineered hybrid MalE proteins were easily purified and demonstrated immunogenicity.
- Specific B-cell and T-cell responses were induced against the inserted viral epitopes.
- Delivery by live bacteria elicited antibody responses against both the MalE carrier and the B-cell epitope, and induced T-cell responses.
Conclusions:
- Hybrid MalE proteins are effective carriers for immunogenic peptides.
- Bacterial delivery systems can enhance the immunogenicity of hybrid proteins, inducing both humoral and cellular immunity.
- This approach shows promise for developing novel vaccine strategies.